» Articles » PMID: 35726299

Exploring the Role of Posttranslational Modifications in Spinal and Bulbar Muscular Atrophy

Overview
Specialty Molecular Biology
Date 2022 Jun 21
PMID 35726299
Authors
Affiliations
Soon will be listed here.
Abstract

Spinal and Bulbar Muscular Atrophy (SBMA) is an X-linked adult-onset progressive neuromuscular disease that affects the spinal and bulbar motor neurons and skeletal muscles. SBMA is caused by expansion of polymorphic CAG trinucleotide repeats in the () gene, resulting in expanded glutamine tract in the AR protein. Polyglutamine (polyQ) expansion renders the mutant AR protein toxic, resulting in the formation of mutant protein aggregates and cell death. This classifies SBMA as one of the nine known polyQ diseases. Like other polyQ disorders, the expansion of the polyQ tract in the AR protein is the main genetic cause of the disease; however, multiple other mechanisms besides the polyQ tract expansion also contribute to the SBMA disease pathophysiology. Posttranslational modifications (PTMs), including phosphorylation, acetylation, methylation, ubiquitination, and SUMOylation are a category of mechanisms by which the functionality of AR has been found to be significantly modulated and can alter the neurotoxicity of SBMA. This review summarizes the different PTMs and their effects in regulating the AR function and discusses their pathogenic or protective roles in context of SBMA. This review also includes the therapeutic approaches that target the PTMs of AR in an effort to reduce the mutant AR-mediated toxicity in SBMA.

Citing Articles

Functional Implications of Protein Arginine Methyltransferases (PRMTs) in Neurodegenerative Diseases.

Angelopoulou E, Pyrgelis E, Ahire C, Suman P, Mishra A, Piperi C Biology (Basel). 2023; 12(9).

PMID: 37759656 PMC: 10525691. DOI: 10.3390/biology12091257.


Implications of specific lysine residues within ataxin-3 for the molecular pathogenesis of Machado-Joseph disease.

Pereira Sena P, Weber J, Bayezit S, Saup R, Incebacak Eltemur R, Li X Front Mol Neurosci. 2023; 16:1133271.

PMID: 37273907 PMC: 10235640. DOI: 10.3389/fnmol.2023.1133271.

References
1.
Chua J, Reddy S, Yu Z, Giorgetti E, Montie H, Mukherjee S . Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease. J Clin Invest. 2015; 125(2):831-45. PMC: 4319414. DOI: 10.1172/JCI73214. View

2.
Tsai M, OMalley B . Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994; 63:451-86. DOI: 10.1146/annurev.bi.63.070194.002315. View

3.
Bott L, Badders N, Chen K, Harmison G, Bautista E, Shih C . A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Hum Mol Genet. 2016; 25(10):1979-1989. PMC: 5062587. DOI: 10.1093/hmg/ddw073. View

4.
Bevan C, Hughes I, Patterson M . Wide variation in androgen receptor dysfunction in complete androgen insensitivity syndrome. J Steroid Biochem Mol Biol. 1997; 61(1-2):19-26. DOI: 10.1016/s0960-0760(97)00001-0. View

5.
Ramazi S, Zahiri J . Posttranslational modifications in proteins: resources, tools and prediction methods. Database (Oxford). 2021; 2021. PMC: 8040245. DOI: 10.1093/database/baab012. View